Be Biopharma Company Profile

Background

Overview

Be Biopharma, founded in October 2020, is a clinical-stage biotechnology company pioneering the development of Engineered B Cell Medicines (BCMs). The company focuses on harnessing the therapeutic potential of B cells to address serious conditions such as Hemophilia B, Hypophosphatasia (HPP), and various cancers. By engineering B cells to produce therapeutic proteins, Be Biopharma aims to create durable, re-dosable, and allogeneic cell therapies that can be administered without pre-conditioning.

Mission and Vision

Be Biopharma's mission is to revolutionize medicine by leveraging the natural protein-producing capabilities of B cells to develop innovative therapies for patients with unmet medical needs. The company's vision is to establish BCMs as a transformative class of cellular medicines, offering durable and re-dosable treatments across a broad spectrum of diseases.

Industry Significance

The biotechnology industry is increasingly recognizing the potential of cell-based therapies. Be Biopharma's focus on BCMs positions it at the forefront of this innovation, with the potential to significantly impact the treatment landscape for various genetic disorders and cancers.

Key Strategic Focus

Core Objectives

• Development of BCMs: Advance the engineering of B cells to produce therapeutic proteins for the treatment of serious diseases.

• Clinical Advancement: Progress pipeline candidates through clinical trials to establish safety and efficacy.

• Platform Expansion: Expand the BCM platform to address a wide range of therapeutic areas.

Areas of Specialization

• Hemophilia B: Developing BE-101, a BCM designed to provide continuous levels of Factor IX.

• Hypophosphatasia (HPP): Advancing BE-102, a BCM aimed at producing active alkaline phosphatase to address bone mineralization issues.

• Oncology: Exploring the use of BCMs in cancer immunotherapy.

Key Technologies Utilized

• CRISPR/Cas9 Gene Editing: To precisely modify B cells for therapeutic protein production.

• Artificial Intelligence-Guided Protein Design: To optimize the activity and stability of therapeutic proteins produced by engineered B cells.

Primary Markets Targeted

• Rare Genetic Diseases: Such as Hemophilia B and HPP.

• Cancer: Particularly hematologic malignancies.

• Broad Therapeutic Areas: Including autoimmune diseases and enzyme deficiencies.

Financials and Funding

Total Funds Raised

Be Biopharma has secured over $260 million in funding since its inception.

Recent Funding Rounds

• Series A Financing (October 2020): Raised $52 million led by Atlas Venture and RA Capital Management, with participation from Alta Partners, Longwood Fund, and Takeda Ventures.

• Series B Financing (April 2022): Closed a $130 million round led by ARCH Venture Partners, with participation from Bristol Myers Squibb and other investors.

• Additional Financing (October 2024): Secured $82 million from ARCH Venture Partners, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund, Bristol Myers Squibb, and Takeda Ventures to advance BE-101 and BE-102.

Utilization of Capital

The funds have been allocated to:

• Advancing the BCM platform.

• Progressing pipeline candidates through clinical trials.

• Expanding manufacturing capabilities.

• Strengthening the leadership team.

Pipeline Development

BE-101 for Hemophilia B

• Stage: Phase 1/2 clinical trial (BeCoMe-9) initiated in July 2025.

• Target Condition: Hemophilia B.

• Anticipated Milestones: Completion of initial dosing and preliminary efficacy assessments.

BE-102 for Hypophosphatasia

• Stage: Preclinical development.

• Target Condition: Hypophosphatasia.

• Anticipated Milestones: IND submission and initiation of clinical trials.

Technological Platform and Innovation

Proprietary Technologies

• BCM Platform: Engineered B cells producing therapeutic proteins.

• CRISPR/Cas9 Gene Editing: For precise genetic modifications.

• AI-Guided Protein Design: To enhance protein activity and stability.

Significant Scientific Methods

• Ex Vivo Gene Editing: Modifying autologous B cells outside the body.

• In Vivo Engraftment Studies: Assessing long-term engraftment and protein production.

Leadership Team

Executive Profiles

• Joanne Smith-Farrell, Ph.D. – Chief Executive Officer and Director

• Former CEO of a cell and gene therapy company.

• Expert in advancing cellular therapies.

• Rick Morgan, Ph.D. – Chief Scientific Officer

• Specialist in cell and gene therapies.

• Led preclinical development of BCMs.

• Angus Smith – Chief Financial Officer

• Over 15 years in biotechnology finance.

• Former CFO of Affimed N.V.

• Wing-Yen Wong, M.D. – Interim Chief Medical Officer

• 35 years in clinical development.

• Former Group Vice-President at BioMarin.

Recent Leadership Changes

• Angus Smith joined as CFO in January 2024.

• Wing-Yen Wong, M.D. appointed as interim CMO in January 2024.

Competitor Profile

Market Insights and Dynamics

• Market Size: The global cell and gene therapy market is rapidly expanding, with significant investments in research and development.

• Growth Potential: High demand for innovative treatments for rare diseases and cancers.

• Industry Trends: Shift towards personalized and durable therapies.

Competitor Analysis

• BeOne Medicines (formerly BeiGene): Focuses on oncology treatments.

• Eurofins: Provides laboratory services supporting biopharmaceutical development.

• Incyte: Specializes in oncology and immunology.

Strategic Collaborations and Partnerships

• ARCH Venture Partners: Led Series B financing.

• Bristol Myers Squibb: Participated in Series B financing.

• Takeda Ventures: Invested in Series A and B financings.

Operational Insights

Strategic Considerations

• Major Competitors: BeOne Medicines, Eurofins, Incyte.

• Market Position: Emerging leader in BCM development.

• Competitive Advantages: Proprietary BCM platform, strong investor backing, experienced leadership.

Strategic Opportunities and Future Directions

Strategic Roadmap

• Clinical Advancement: Progress BE-101 and BE-102 through clinical trials.

• Platform Expansion: Develop BCMs for additional therapeutic areas.

• Partnerships: Form strategic alliances to enhance development capabilities.

Future Business Directions

• Global Expansion: Extend reach to international markets.

• Regulatory Approvals: Achieve IND approvals for new candidates.

• Commercialization: Prepare for product launches in key markets.

Contact Information

• Official Website: be.bio

• LinkedIn: Be Biopharma LinkedIn